Drug intelligence / Profile preview

AK-3012

Development stage: Phase 2
Lead developer: Dolorgiet
Modality: Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Subcutaneous, Topical

Overview

AK-3012 is a proprietary topical formulation developed for the treatment of actinic keratosis, a precancerous skin condition. The drug is administered subcutaneously or topically, and its active ingredient is designed to inhibit the progression of actinic keratosis lesions[1][4]. Clinical trials have evaluated different concentrations of AK-3012 for safety and efficacy in patients with actinic keratosis[2][3]. The developer associated with clinical studies is Dolorgiet GmbH & Co. KG[7]. The precise mechanism of action and the specific molecular target(s) for AK-3012 are not publicly disclosed in available sources.

Beyond the preview

Go deeper on AK-3012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AK-3012.

Explore the full profile